Abstract
Despite important advances made in the last century, infectious diseases caused by pathogenic microrganisms are still a major threat to human health. This is worsened by the occurrence of new forms of bacterial resistance against antibiotics, that are the main remedy against infectious diseases, and their rapid spreading across bacterial species, pose additional threats to our health. Thus, the necessity to develop new weapons against pathogenic bacteria is widely recognized as a major challenge for modern drug research. Traditional antibiotic discovery procedures have so far focused on inhibiting the main processes of the bacterial cell (replication, transcription, translation, and peptidoglycan synthesis). This review will give an overview of the therapeutic strategies to cure infectious diseases caused by Gram-negative bacteria through the development of inhibitors of Kdo biosynthesis. Kdo is a monsaccharide essential for OM biogenesis, OM being an essential cellular structure shared by all Gram-negative bacteria. Hence, inhibitors of its biosynthesis can have a broad-spectrum antibacterial activity.
Keywords: LPS, enzyme inhibitors, Kdo, Lipid A, Gram-negative bacteria, antibiotics, enzyme structure
Current Drug Discovery Technologies
Title: The Kdo Biosynthetic Pathway Toward OM Biogenesis as Target in Antibacterial Drug Design and Development
Volume: 6 Issue: 1
Author(s): Laura Cipolla, Alessandra Polissi, Cristina Airoldi, Paolo Galliani, Paola Sperandeo and Francesco Nicotra
Affiliation:
Keywords: LPS, enzyme inhibitors, Kdo, Lipid A, Gram-negative bacteria, antibiotics, enzyme structure
Abstract: Despite important advances made in the last century, infectious diseases caused by pathogenic microrganisms are still a major threat to human health. This is worsened by the occurrence of new forms of bacterial resistance against antibiotics, that are the main remedy against infectious diseases, and their rapid spreading across bacterial species, pose additional threats to our health. Thus, the necessity to develop new weapons against pathogenic bacteria is widely recognized as a major challenge for modern drug research. Traditional antibiotic discovery procedures have so far focused on inhibiting the main processes of the bacterial cell (replication, transcription, translation, and peptidoglycan synthesis). This review will give an overview of the therapeutic strategies to cure infectious diseases caused by Gram-negative bacteria through the development of inhibitors of Kdo biosynthesis. Kdo is a monsaccharide essential for OM biogenesis, OM being an essential cellular structure shared by all Gram-negative bacteria. Hence, inhibitors of its biosynthesis can have a broad-spectrum antibacterial activity.
Export Options
About this article
Cite this article as:
Cipolla Laura, Polissi Alessandra, Airoldi Cristina, Galliani Paolo, Sperandeo Paola and Nicotra Francesco, The Kdo Biosynthetic Pathway Toward OM Biogenesis as Target in Antibacterial Drug Design and Development, Current Drug Discovery Technologies 2009; 6 (1) . https://dx.doi.org/10.2174/157016309787581093
DOI https://dx.doi.org/10.2174/157016309787581093 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novelty in Inflammation and Immunomodulation in Migraine
Current Pharmaceutical Design Motor Neuron Disease and Acquired Axonal Neuropathy Association in HIV Infection: Case Report and Update
Current HIV Research Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry The Blood-Central Nervous System Barriers Actively Control Immune Cell Entry into the Central Nervous System
Current Pharmaceutical Design Antiviral Drug Discovery Targeting to Viral Proteases
Current Pharmaceutical Design Olfactory Ensheathing Cells Protect Cortical Neuron Cultures Exposed to Hypoxia
CNS & Neurological Disorders - Drug Targets The Premature Lottery in the Canadian Grey Zones
Current Pediatric Reviews Turning Up the Pressure on Vascular Disease
Current Neurovascular Research Systematic Review and Meta-analysis of Carbapenem Resistance of Acinetobacter baumannii in Iran
Infectious Disorders - Drug Targets Recent Advances in Research on the Most Novel Carbonic Anhydrases,CA XIII and XV
Current Pharmaceutical Design Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Myelin Sheaths and Autoimmune Response Induced by Myelin Proteins and Alphaviruses. I. Physicochemical Background
Current Medicinal Chemistry Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects
CNS & Neurological Disorders - Drug Targets Targeting the Methyl Erythritol Phosphate (MEP) Pathway for Novel Antimalarial, Antibacterial and Herbicidal Drug Discovery: Inhibition of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase (DXR) Enzyme
Current Pharmaceutical Design Potential of Selected Antioxidants for Influenza Chemotherapy
Anti-Infective Agents in Medicinal Chemistry Recent Progress on Antifungal Drug Development
Current Pharmaceutical Biotechnology Blood-Brain Barrier Transport of Short Proline-Rich Antimicrobial Peptides
Protein & Peptide Letters Diagnostic Value of CRP, Procalcitonin, and Ferritin Levels in Cerebrospinal Fluid of Children with Meningitis
Central Nervous System Agents in Medicinal Chemistry An Overview of the Current and Novel Drugs for Alzheimers Disease with Particular Reference to Anti-Cholinesterase Compounds
Current Pharmaceutical Design